Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to $1.7 million.

  • Pharma's Total Liabilities fell 4481.95% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 4481.95%. This contributed to the annual value of $2.4 million for FY2025, which is 635.41% down from last year.
  • According to the latest figures from Q3 2025, Pharma's Total Liabilities is $1.7 million, which was down 4481.95% from $1.9 million recorded in Q2 2025.
  • Pharma's Total Liabilities' 5-year high stood at $3.1 million during Q1 2021, with a 5-year trough of $1.7 million in Q3 2025.
  • For the 5-year period, Pharma's Total Liabilities averaged around $2.4 million, with its median value being $2.4 million (2025).
  • Its Total Liabilities has fluctuated over the past 5 years, first surged by 3274.53% in 2023, then plummeted by 4481.95% in 2025.
  • Over the past 5 years, Pharma's Total Liabilities (Quarter) stood at $1.8 million in 2021, then decreased by 3.31% to $1.8 million in 2022, then rose by 25.84% to $2.2 million in 2023, then increased by 27.79% to $2.8 million in 2024, then plummeted by 41.43% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $1.9 million for Q2 2025, and $2.4 million during Q1 2025.